The Interview Issue: John Lechleiter
John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.
John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.
Eugene White, the president of Martin University, had become restless in retirement when the opportunity to lead the struggling black liberal arts college surfaced.
Dr. Mercy Obeime takes annual mission trips to impoverished countries while also serving as medical director of a health clinic in Garfield Park.
Since President Obama’s health law passed in 2010, deductibles on employer health plans have risen nearly seven times faster than wages and nearly three times faster than premiums, leaving consumers exposed more than ever to the sky-high cost of care.
With the number of applications to Marian’s College of Osteopathic Medicine running twice as high as initially expected, school leaders say they are confident Marian can help reduce a looming physician shortage in Indiana.
It looks like Eli Lilly and Co. finally has a drug that can replace its former stars Zyprexa and Cymbalta. The most bullish analysts think Jardiance can surpass those $5 billion-a-year blockbusters.
When hospitals employ doctors—which is now the norm in central Indiana—more of those doctors’ patients end up going to hospitals with higher costs and poorer quality, according to a new study.
A flood of money from Obamacare—for the expanded Healthy Indiana Plan and for private health insurance purchased on the federal exchange—is boosting revenue and profit among Indiana health insurers.
The Central Indiana Corporate Partnership wants the city to improve streets, walkways and other infrastructure around the 170-acre project north of the IUPUI campus, designed to attract high-tech businesses and workers.
Four of the 10 metro areas that will see the biggest decrease in competition from the Anthem-Cigna merger are in Indiana, according to an analysis by the American Medical Association—with Indianapolis facing the second-biggest impact among all of Anthem’s markets nationwide.
The controversial co-founder and former CEO of life insurance giant Conseco Inc. (now CNO Financial Group Inc.) spearheaded the purchase of a small life insurance company operated out of Texas and plans to gradually build up its operations here.
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
CEO Bryan Mills has set a goal to make 75 percent of revenue—or $1.5 billion a year—be covered by value-based contracts—which means Community would be rewarded for keeping patients out of the hospital. A new venture is Mills’ strategy to get there.
USA Funds’ business is dying. But the Fishers-based not-for-profit with nearly $600 million in annual revenue is determined to find new life helping students pay for college degrees.
Marian University expects the deans of both its medical and nursing schools to retire in the next two years. So, the small Catholic school is launching a search for replacements.
More paying customers helped Community Health Network pull in $47 million in second-quarter profits, a story being repeated at not-for-profit hospitals around the country as Obamacare has boosted the number of insured customers to unprecedented highs.
Providence Cristo Rey is one of a handful of Indiana schools with overwhelming numbers of low-income students that is achieving results at least as good as or better than the state average.
A recent study found the number of health insurers offering broad provider networks on the Obamacare exchange was higher than in all but 10 other states and suggests that so long as Hoosiers keep singing “Don’t Fence Me In,” they could keep paying more for health insurance.
Calibrium LLC and MB2 LLC, both based in Carmel, have agreed to be sold for undisclosed amounts. They were developing diabetes drugs discovered by the research team of Richard DiMarchi, a chemistry professor at Indiana University.
Timothy E. Cook funded his personal expenses by falsely promoting stock in his Indianapolis-based cancer research firm Xytos Inc. long after it had ceased operations, according to a federal court ruling.